Mutations in the PIK3C2B, ERBB3, KIT, and MLH1 Genes and Their Relationship with Resistance to Temozolomide in Patients with High-Grade Gliomas
Considering the results obtained, we suggest that mutations in the four genes and methylation of the gene promoter that codes for the MGMT protein could be related to response to treatment with temozolomide.
Authors
- Fernando P. Monroy (ORCID: https://orcid.org/0000-0002-3466-7466)
- León Darío Ortiz (ORCID: https://orcid.org/0000-0002-1601-5237)
- Ronald Guillermo Pelaez Sánchez (ORCID: https://orcid.org/0000-0002-2815-9844)
- Sara Vélez Gómez (ORCID: https://orcid.org/0000-0001-9818-807X)
- David Andrés Galvis Pareja
- Jorge Emilio Salazar Flórez (ORCID: https://orcid.org/0000-0002-7666-9099)
- Heidy Johanna Contreras Martínez
Institutions
- Saint Martin University (CO)
- Northern Arizona University (US)
- Instituto de Cancerología Las Américas (CO)
- Universidad CES (CO)
- Clínica CES (CO)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-12-06
- DOI
- https://doi.org/10.3390/biomedicines12122777
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.88
Funders
- Universidad CES